Dr. Adher Elsayed


Consultant medical oncology at Kfsh and RC Riyadh


Friday 3-5-2024 Day 1

Advanced HER2-positive/HER2-low breast cancer

Patient with brain metastasis and stable extracranial disease:  when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis:  T-DXd  vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd 
Role of repeated biopsies to guide ADCs in HER2-low BC

Moderator:  Shereef Elsamany



Friday 3-5-2024 Day 1

Can we de-escalate axillary surgery/omit adjuvant radiotherapy with excellent response after NAC?

Complete response to NAC
Residual ITCs after NAC
Controversies of targeted axillary dissection
SLNB: Negative LNs in frozen section/positive in final pathology
Negative SLNB after neoadjuvant hormonal therapy

Moderator:Dr. Nasser Ali Al-Dhaibani Dr. Roaa Attieh



Friday 3-5-2024 Day 1

Genomic tools in breast cancer

  •  chemotherapy in high risk lobular/mucinous BC?
  • Neoadjuvant therapy in premenopausal patients with lobular BC?
    Adjuvant therapy with node negative and node positive lobular BC?
    Adjuvant therapy in luminal BC with RS 16-25?
    Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours??
  • Oncotype DX and selection of neoadjuvant  hormonal vs chemotherapy  therapy
  • Role of interval Ki67 assessment with neoadjuvant  hormonal therapy

Moderator: Ahmed Alshehri